McKesson (MCK) is a 'Buy' with high-growth potential in healthcare services. Learn key risks and outlook for stock ...

McKesson (MCK) stock earns a BUY rating as it excels in tech-driven healthcare, specialty growth, and strong earnings ...

McKesson's fair value estimate has been raised from $793.21 to $829.57, driven by an improved outlook from analysts following ...

McKesson (MCK) delivered its latest quarterly results, reporting a 23% rise in revenue, a 15% higher dividend, and an upward ...

McKesson (MCK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

McKesson Corp on Tuesday said it and two other major U.S. drug distributors could be expected to pay up to $21 billion under a new proposal to resolve thousands of lawsuits alleging they helped fuel ...

McKesson (NYSE: MCK) has outperformed the market over the past 10 years by 2.25% on an annualized basis producing an average annual return of 14.73%. Currently, McKesson has a market capitalization of ...

McKesson on Tuesday raised its profit forecast, as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth.

McKesson MCK is making a strategic shift that will redefine its role in the healthcare ecosystem. Long known as one of the ...

Following the announcement of the updated organizational structure, McKesson is initiating long-term Adjusted Segment Operating Profit growth targets for its newly defined segments, as follows: ...

McKesson is moving forward with a planned spin-off of its Medical-Surgical Solutions business, aiming to bring both organizations into “sharper focus.” ...